MariMed director gains 192,308 shares via RSU grant

MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees.

Rhea-AI Filing Summary

MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees. The RSUs vested upon grant and converted one-for-one into 192,308 shares of common stock at no cash exercise price, increasing his direct holdings to 743,452 shares. No RSUs from this award remain outstanding.

Insider Trade Summary

192,308 shares exercised/converted

Exercise 3 txns

Insider Allen David R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSU) F1, F2	192,308	$0.00	$0.00
Exercise	Restricted Stock Units (RSU) F1, F2	192,308	$0.00	$0.00
Exercise	Common stock F1	192,308	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSU) — 0 contracts (Direct); Common stock — 743,452 shares (Direct)

Footnotes (2)

1. F1. RSUs convert to shares of common stock on a one-for-one basis.
2. F2. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.

Key Figures

RSUs granted: 192,308 units Common shares acquired: 192,308 shares Total shares held after transaction: 743,452 shares +2 more

5 metrics

RSUs granted 192,308 units Restricted Stock Units granted on July 15, 2026 in lieu of board fees

Common shares acquired 192,308 shares Shares of common stock received upon RSU vesting and conversion on July 15, 2026

Total shares held after transaction 743,452 shares Direct holdings of MariMed common stock by Allen David R following the RSU conversion

Exercise price per share $0.00 per share Cash exercise price for conversion of RSUs into common stock

Underlying common shares per RSU 1 share per RSU RSUs convert to shares of common stock on a one-for-one basis

Key Terms

Restricted Stock Units (RSU), derivative security, in lieu of cash, Rule 10b5-1

4 terms

Restricted Stock Units (RSU) financial

"The RSUs were granted in lieu of cash as payment for a portion"

derivative security financial

"transaction_action": "derivative exercise/conversion""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

in lieu of cash financial

"RSUs were granted in lieu of cash as payment for a portion"

Rule 10b5-1 financial

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity compensation did MariMed (MRMD) director Allen David R receive?

Allen David R received 192,308 Restricted Stock Units on July 15, 2026 as compensation for a portion of his MariMed board fees. These RSUs vested immediately and converted one-for-one into 192,308 shares of common stock at no cash exercise price.

How many MariMed (MRMD) shares does Allen David R hold after these transactions?

Following the RSU grant and conversion, Allen David R directly holds 743,452 shares of MariMed common stock. This total reflects the addition of 192,308 shares received upon the vesting and conversion of his Restricted Stock Units granted as director compensation.

How did the 192,308 RSUs for MariMed (MRMD) convert into common shares?

The 192,308 RSUs convert into MariMed common stock on a one-for-one basis, as disclosed. Upon grant on July 15, 2026, the RSUs vested immediately and were exercised or converted into 192,308 shares of common stock with no cash exercise price.

Were the MariMed (MRMD) RSU-related transactions made under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox for these MariMed transactions was not marked as true, indicating they were not affirmatively reported as executed pursuant to a Rule 10b5-1 trading plan. The activity instead reflects compensation-related RSU grant and conversion.

Do any RSUs from this MariMed (MRMD) award remain outstanding for Allen David R?

No RSUs from this award remain outstanding. The footnotes state that the 192,308 RSUs granted on July 15, 2026 vested upon grant and, accordingly, no RSUs remain outstanding under this award after their conversion into common shares.

Why were RSUs used instead of cash to compensate the MariMed (MRMD) director?

The company states the RSUs were granted in lieu of cash as payment for a portion of Allen David R’s fees for serving on MariMed’s Board of Directors, effectively delivering board compensation in equity rather than in cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allen David R

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	07/15/2026		M		192,308	A	$0(1)	743,452	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	07/15/2026		A		192,308		(2)	(2)	Common Stock, par value $.001 per share	192,308	$0	192,308	D
Restricted Stock Units (RSU)	(1)	07/15/2026		M			192,308	(2)	(2)	Common Stock, par value $.001 per share	192,308	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ David R. Allen	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)